ClinicalTrials.gg
Not yet recruitingNCT07205016Updated Oct 3, 2025

FreeFrail Project: A Multicomponent Intervention for the Management of Frailty in Primary Care: A Randomized Controlled Trial

An interventional study of Dual task exercise and Otago exercise in Frail Elderly, Dual Task Exercises in Elderly People and Exercise Training, sponsored by Universitat de Lleida. Not yet recruiting. Open to participants aged 65 Years and older. Per ClinicalTrials.gov, last updated 2025-10-03.

Sponsored by Universitat de Lleida · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Primary completion was expected by Jul 2026, 4 months ago, but the record still lists the study as not yet recruiting.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
220
Allocation
Randomized
Ages
65 Years and older
Sex
All
01

Study summary

The primary aim is to assess the effectiveness of a multicomponent intervention including dual-task exercise in improving functionality and cognitive performance and in reducing frailty among community-dwelling adults aged ≥65 years compared to usual care. Secondary objectives include evaluating its impact on pain, anxiety or depression, sleep quality, quality of life, physical activity, handgrip strength, and polypharmacy.

A double-blind, randomized, parallel-group controlled trial will be conducted in primary care centers in Lleida. Frail older adults (≥65 years) will be recruited and randomly allocated to either the intervention group, receiving a structured cognitive-motor dual-task based multicomponent program, or the control group, receiving usual care. Outcomes will be assessed using validated tools at baseline and follow-up.

02

Conditions studied

  • Frail Elderly
  • Dual Task Exercises in Elderly People
  • Exercise Training
  • Frailty

Browse trials for

Keywords

  • primary care Health [MeSH]
  • multicomponent intervention
  • exercise therapy [MeSH]
  • cognitive-motor dual-task
  • frail elderly [MeSH]
  • frailty [MeSH]
03

In context

Frailty

1,291 studies on the registry are indexed under Frailty; 454 are open to participants now.

This study's planned enrollment of 220 is above the median of 83 across 772 interventional studies indexed under Frailty.

Browse Frailty studies →

Lead sponsor

Universitat de Lleida is the lead sponsor of 33 studies on the registry; 19 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
65 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Aged 65 or older
  • Frailty according to Fragil-VIG index (>0,20)
  • Barthel index > 60
  • Able to perform physical exercise
  • Able to understand and communicate in Catalan or Spanish

Exclusion criteria

Exclusion Criteria:

  • Decompensated / Unstable cardiovascular disease or recent diagnosed
  • Upper or lower injury with functional impairment
  • Institutionalized patient.
  • Terminal or tumoral processes
  • People who participated in another clinical trial or exercise programme during last year
  • Diagnosis of severe dementia
05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Investigator, Outcomes assessor)
Enrollment
220 participants (estimated)

Study arms

  • Experimental
    Experimental

    The intervention group will conduct the same multicomponent intervention than the control group, but adding the dual cognitive task while performing the therapeutic physical activity, which may include counting numbers backwards, in 2s, mentioning names of animals, food, countries and others. The objective of this additional condition is to stimulate cognitive and functional capacity simultaneously, increasing the complexity of the activity and the transfer to daily life activities

    Behavioral: Dual task exercise

  • Active comparator
    Control

    A multicomponent program designed to address frailty in community-dwelling older adults. It integrates three evidence-based domains: therapeutic physical activity, cognitive psychological intervention, and nutritional support. The three components are delivered in a coordinated manner by a multidisciplinary team at ICS. Intervention fidelity is ensured through standardized protocols, training of professionals, and monitoring of adherence. The therapeutic physical activity program will be structured across three progressive levels-beginner, intermediate, and advanced-to accommodate varying functional capacities. Strength training will advance through incremental increases in repetitions and resistance, while balance exercises will become more challenging by reducing external support. The material for the session will be in the same room where the group is held and will include the use of weights or dumbbells, elastic bands, balls, and pikes

    Behavioral: Otago exercise

Interventions

  • BehavioralDual task exercise

    The intervention group will conduct the same multicomponent intervention than the control group, but adding the dual cognitive task while performing the therapeutic physical activity, which may include counting numbers backwards, in 2s, mentioning names of animals, food, countries and others. The objective of this additional condition is to stimulate cognitive and functional capacity simultaneously, increasing the complexity of the activity and the transfer to daily life activities.

  • BehavioralOtago exercise

    The proposed intervention is a multicomponent program designed to address frailty in community-dwelling older adults. It integrates three evidence-based domains: therapeutic physical activity, cognitive psychological intervention, and nutritional support.

06

What researchers measure

Primary outcomes

  1. Physical performance and functional status

    The Short Physical Performance Battery (SPPB) is an ordinal quantitative scale ranging from 0 to 12. This validated tool assesses three functional domains: lower-limb muscle strength, by timing the repeated chair-stand test; gait speed, through the 4-meter walking test; and static balance, evaluated with three progressively difficult positions (feet together, semi-tandem, tandem). A composite score is calculated, with lower values reflecting poorer performance. A score of 9 or less has been widely adopted as a cut-off point for identifying frailty and pre-frailty in older adults, making this instrument particularly suitable for evaluating the effectiveness of interventions on physical function

    Time frame: From enrollment to the end of treatment at 12 weeks

  2. Cognitive function

    The Mini-Mental State Examination (MMSE) is a continuous quantitative widely used 30-point screening tool validated for older adults to assess global cognitive function. It evaluates orientation, memory, attention, language, and praxis, providing a standardized quantitative measure of cognitive status. Although limited in sensitivity for mild or executive deficits, the MMSE remains a practical first-line assessment in frailty research and clinical protocols, and its integration alongside multidimensional frailty measures allows for a more comprehensive characterization of cognitive vulnerability in aging. A culturally adapted and validated version is available in Spanish, enabling its use in Hispanic populations.

    Time frame: From enrollment to the end of treatment at 12 weeks

  3. Frailty status

    The Frailty-VIG is an ordinal quantitative measure specifically validated for older adults in the community. This multidimensional tool comprises 22 dichotomous items spanning activities of daily living, nutrition, cognition, emotional health, social context, geriatric syndromes, and chronic diseases. By incorporating multimorbidity and psychosocial domains alongside physical aspects, the Frailty-VIG provides a comprehensive assessment of frailty, overcoming the limitations of purely physical indices

    Time frame: From enrollment to the end of treatment at 12 weeks

Secondary outcomes

  1. Quality of life / Anxiety and Depression / Pain severity

    will be evaluated with the EuroQoL-5D-5L which generates ordinal categorical variables from five dimensions of health: mobility, self-care, usual activities, pain/discomfort, and anxiety/depression. Each dimension is rated on a five-point Likert scale, where higher scores denote lower quality of life. This standardized and validated instrument has been extensively applied in Spanish populations and is particularly appropriate to capture the multidimensional impact of frailty on health-related quality of life

    Time frame: From enrollment to the end of treatment at 12 weeks

  2. Sleep performance

    will be assessed using the Spanish validated version of the Pittsburgh Sleep Quality Index (PSQI). This self-administered questionnaire yields a global score between 0 and 21, with higher scores reflecting worse sleep quality. It evaluates seven components-subjective quality, latency, duration, habitual efficiency, disturbances, medication use, and daytime dysfunction. A score above 5 is commonly considered indicative of clinically relevant sleep impairment. As poor sleep has been consistently associated with frailty and functional decline, the PSQI offers a sensitive and appropriate measure for this study

    Time frame: From enrollment to the end of treatment at 12 weeks

  3. Physical activity

    will be assessed through the International Physical Activity Questionnaire (IPAQ), which produces continuous quantitative data expressed in metabolic equivalent task minutes per week (MET-min/week). It includes seven open questions regarding activity over the previous seven days, covering walking, moderate and vigorous activities, and sedentary behaviour. The calculation of MET-min/week allows standardized estimation of global activity levels. This questionnaire is validated and widely used in community-dwelling adults, making it an appropriate measure for capturing the impact of the intervention on activity levels

    Time frame: From enrollment to the end of treatment at 12 weeks

  4. Handgrip strength

    will be measured with a handheld dynamometer. Results are expressed as continuous quantitative variables in kilograms. Following standardized protocols, participants will be seated with the elbow flexed at 90° and the wrist positioned between neutral and 30° dorsiflexion. They will be instructed to squeeze the dynamometer maximally for 3-5 seconds. Three trials will be performed alternately in each hand, with one-minute rest intervals, and the best value will be recorded. Handgrip strength is a simple, reliable, and validated marker of sarcopenia and frailty risk, strongly correlated with morbidity and mortality in older adults

    Time frame: From enrollment to the end of treatment at 12 weeks

  5. Inflammatory and mitochondrial function biomarkers

    are strongly supported by the literature in frail population, as these biological factors are fundamentally implicated in the pathways leading to frailty, sarcopenia, and functional impairment. Chronic low-grade inflammation ("inflammaging"), a hallmark of aging, is characterized by increased levels of circulating pro-inflammatory cytokines such as interleukin 6 and 8(IL-6, IL-8), interleukin 1β (IL-1β), tumor necrosis factor-α (TNF-α), and C-reactive protein (CRP). These biomarkers consistently correlate with chronic low-grade inflammation ("inflammaging") and mitochondrial dysfunction (3) they have also been consistently associated with sarcopenia, frailty, and functional decline (4,5) . The blood samples will be analysed at Biomedical Research Institute of Lleida (IRB Lleida), generating continuous quantitative data.

    Time frame: From enrollment to the end of treatment at 12 weeks

07

Study locations

No study locations are listed for this record.

08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Jan 2026; primary completion for Jul 2026, 6 months later.

Of 514 non-industry interventional studies with no phase under Frailty, half reached primary completion within 22 months of starting (the median), counting those still running; a quarter within 11 and three quarters within 39. This study's planned 6 months is below that.

Counting every sponsor, half of 519 studies reached it within 22 months; a quarter within 10 and three quarters within 39.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 24, 2025
First posted
Oct 3, 2025
StartEst.
Jan 2026
Primary completionEst.
Jul 2026
CompletionEst.
Oct 2026
Last update
Oct 3, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Oct 3, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07205016
Lead sponsor
Universitat de Lleida
Collaborators
Institut Catala de Salut
Responsible party
Oriol Martínez Navarro (Doctor, Universitat de Lleida) — Principal investigator
First posted
Oct 3, 2025
Start date
Jan 2026 (estimated)
Primary completion
Jul 2026 (estimated)
Completion
Oct 2026 (estimated)
Last update
Oct 3, 2025

Study contacts

Oriol Martínez-Navarro, Doctor
Contact
oriol.martinez@udl.cat
619562618

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Sep 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion